NeoGenomics (NEO) to Release Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) will likely be releasing its earnings data before the market opens on Tuesday, February 18th. Analysts expect NeoGenomics to post earnings of $0.03 per share and revenue of $173.40 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

NeoGenomics Stock Performance

NASDAQ NEO opened at $13.51 on Tuesday. The firm has a market cap of $1.73 billion, a P/E ratio of -22.15 and a beta of 1.23. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The company’s 50 day moving average is $16.09 and its 200-day moving average is $15.66. NeoGenomics has a 12-month low of $12.13 and a 12-month high of $19.11.

Insider Activity

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NEO shares. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Friday, January 10th. Bank of America increased their price objective on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Jefferies Financial Group started coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, The Goldman Sachs Group lowered their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, NeoGenomics has an average rating of “Moderate Buy” and an average price target of $20.20.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.